Close
Close

Bayer - Pulmonary arterial hypertension

Partner

Not provided

Rare Disease

Pulmonary arterial hypertension

Sponsor

Bayer

Access Program Information

The aim of the study is to assess safety, tolerability and clinical effects of different doses of Riociguat in patients with inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and who are not satisfactorily treated and cannot participate in any other CTEPH trial. In the US the study runs as an Expanded Access program under 21 CFR 312.320.

Contact
Locations
  • Austria
  • Belgium
  • Canada
  • Colombia
  • Czech Republic
  • Denmark
  • France
  • Germany
  • Italy
  • Japan
  • Mexico
  • Netherlands
  • Portugal
  • Russian Federation
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Kingdom
  • United States
  • Tucson, Arizona, United States
  • United States
  • La Jolla, California, United States
  • Los Angeles, California, United States
  • Sacramento, California, United States
  • United States
  • Aurora, Colorado, United States
  • United States
  • Weston, Florida, United States
  • United States
  • Chicago, Illinois, United States
  • United States
  • Iowa City, Iowa, United States
  • United States
  • Baltimore, Maryland, United States
  • United States
  • Boston, Massachusetts, United States
  • Boston, Massachusetts, United States
  • United States
  • Ann Arbor, Michigan, United States
  • United States
  • Omaha, Nebraska, United States
  • United States
  • Newark, New Jersey, United States
  • United States
  • New York, New York, United States
  • United States
  • Cleveland, Ohio, United States
  • Columbus, Ohio, United States
  • Fairfield, Ohio, United States
  • United States
  • Philadelphia, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • United States
  • Providence, Rhode Island, United States
  • United States
  • Dallas, Texas, United States
  • El Paso, Texas, United States
  • Houston, Texas, United States

Free Newsletter